Last edition
News about "Rapid Ventricular Rate"
Milestone Pharmaceuticals Enrolls First Patient in Phase 3 Trial of Etripamil for AFib-RVR
Milestone Pharmaceuticals has begun its Phase 3 ReVeRA-301 trial to evaluate self-administered etripamil nasal spray for acute AFib-RVR, targeting rapid ventricular rate reduction and symptom relief.
Rapid Ventricular Rate | 24/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members